Relapse or refractory non-Hodgkin's lymphoma

Relapse or refractory non-Hodgkin's lymphoma describes a clinical state of lymphoid malignancy that either returns following a period of complete or partial remission (relapsed) or fails to achieve an adequate objective response or progresses during or shortly after prior therapy (refractory)

Relapse or refractory non-Hodgkin's lymphoma describes a clinical state of lymphoid malignancy that either returns following a period of complete or partial remission (relapsed) or fails to achieve an adequate objective response or progresses during or shortly after prior therapy (refractory) Pathophysiologically, the condition is characterized by treatment-resistant clonal proliferation, persistent lymphadenopathy, splenomegaly, or extranodal organ infiltration

Arising within the lymphatic and hematopoietic systems, this heterogeneous group of clonal B-cell, T-cell, or natural killer–cell neoplasms can affect pediatric or adult populations

Arising within the lymphatic and hematopoietic systems, this heterogeneous group of clonal B-cell, T-cell, or natural killer–cell neoplasms can affect pediatric or adult populations Patients often exhibit treatment-emergent genetic mutations, dysregulated survival signaling pathways, immune evasion, or aggressive histologic transformation that collectively drive therapeutic failure

Patients often exhibit treatment-emergent genetic mutations, dysregulated survival signaling pathways, immune evasion, or aggressive histologic transformation that collectively drive therapeutic failure